ABSTRACT. The glutathione S-transferase (GST) family consists of phase II detoxification enzymes that catalyze the conjugation of toxic substances, such as chemotherapeutic agents, to glutathione. We examined whether GSTT1/GSTT1"null", GSTM1/GSTM1"null" and GSTP1Ile105Ile/GSTP1Ile105Val polymorphisms are associated with different response rates to neoadjuvant chemotherapy in the treatment of stage II and III breast cancer. Forty Brazilian women with invasive ductal adenocarcinoma of the breast submitted to neoadjuvant chemotherapy, using 5-fluorouracil, epirubicin and cyclophosphamide, were genotyped for the GSTT1, GSTM1 and GSTP1 genes. Clinical response was assessed by RECIST criteria. Comparisons were made for the three genes alone and in pairs, as polymorphic and as wildtype combinations and polymorphic/wild-type combinations. We analyzed all possible combinations and their response rate. Patients with the GSTT1/GSTP1105Ile combination were found to have a significantly better response than GSTT1"null"/GSTP1105Val (P = 0.0209) and GSTT1/GSTM1 (P = 0.0376) combinations. Analysis of all possible combinations showed the GSTM1"null" polymorphic genotype to be present in four, and the wild-type GSTP1105Ile in six of the combinations associated with the largest number of responding patients. We found that patients with the GSTT1/GSTP1105Ile wild-type combination had a significantly higher response rate to chemotherapy than patients with the respective polymorphic GSTT1"null"/GSTP1105Val combination or patients with the wildtype GSTT1/GSTM1. The six gene combinations associated with the largest number of responding patients were found to contain the wildtype GSTP1105Ile and the polymorphic-type GSTM1"null". These specific combinations were virtually absent in the combinations with few responding patients.
INTRODUCTION
Breast cancer is the most prevalent gynecological neoplasm with the highest incidence in women worldwide (Parkin et al., 2005) . Late diagnosis of the disease and mechanisms of resistance to chemotherapeutic drugs are the greatest obstacles in treating breast cancer (Leonessa and Clarke, 2003) . Different responses to similar chemotherapy schemes in breast cancer patients, having the same biologic characteristics and stage, suggest different mechanisms of resistance to this therapy, some of which are induced by genetic pathways (Hayes and Pulford, 1995; O'Brien and Tew, 1996; Pakunlu et al., 2003; Rodrigues et al., 2008) . Molecular and biochemical aspects of the cellular resistance process have been described, where the genes of the glutathione S-transferase (GST) family have been shown to play an important role (Hayes and Pulford, 1995; O'Brien and Tew, 1996; Burg and Mulder, 2002; L'Ecuyer et al., 2004) . These mechanisms of cellular resistance include metabolic detoxification by the GST family (Schisselbauer et al., 1990; Tew, 1994; Hayes and Pulford, 1995) . The GSTP1, GSTM1 and GSTT1 genes, which belong to the GST family, encode the most important phase II detoxifying proteins involved in the conjugation of substrates that are toxic to cancer cells, including chemotherapeutic agents used in breast cancer treatment such as anthracyclines (Arrick and Nathan, 1984; Russo and Mitchell, 1985; Townsend and Cowan, 1989; Shea et al., 1990; Tew, 1994; Adler et al., 1999; Burg and Mulder, 2002; Townsend and Tew, 2003a,b; Daly, 2003; McIlwain et al., 2006) .
Of the different classes of genes found in the GST family, the GSTT1 form located on chromosome 22 is the most studied in the GSTT class, while the GSTM1 form located on chromosome 1 has been the most researched in the GSTM class. Both classes have polymorphic null forms (GSTT1"null" and GSTM1"null"), which do not have their two alleles and are therefore unable to encode the detoxifying enzymes (Cho et al., 2001; Townsend and Tew, 2003a,b; McIlwain et al., 2006) . The GSTP class gene located on chromosome 11 has a wildtype form known as GSTP1*A (Ile105Ile/Ala113Ala) and two polymorphic forms known as GSTP1*B (Ile105Val/Ala113Ala) and GSTP1*C (Ile105Val/Ala113Val), which, akin to the "null" forms, do not have their two alleles and therefore are unable to encode the detoxifying enzymes. The GSTM1"null" and GSTP1*B forms are also unable to inhibit their respective apoptosis pathways (ASK1 and JNK1) (Adler et al., 1999; Townsend and Tew, 2003a; Dang et al., 2005) .
A number of different studies have yielded variable, inconsistent results regarding the relationship between the presence of polymorphic forms of GSTs and chemotherapeutic response (Riddick et al., 2005) . Consequently, the aim of this study was to evaluate the clinical response to chemotherapy in patients with stage II and III invasive ductal adenocarcinoma of the breast in the presence of the GSTT1/GSTT1"null", GSTM1/GSTM1"null" and GSTP1Ile105Ile/GSTP1Ile105Val polymorphisms.
MATERIAL AND METHODS

Patients and samples
The study included 40 Brazilian patients diagnosed with stage II or III invasive ductal adenocarcinoma of the breast, who were consecutively referred to the chemotherapy outpatient unit of the Department of Obstetrics and Gynecology at Santa Casa de São Paulo Hospital, between February 2004 and December 2006. Inclusion criteria were as follows: i) a single, unilateral tumor without clinical or radiological signs of metastasis; ii) patient age between 35 and 70 years, and iii) absence of cardiomyopathy. Table 1 lists the patients and tumor characteristics.
The greater diameter of clinical margins of the patients' tumor was measured with pachymeter. It was tattooed before the first session of chemotherapy. Thirty days after the third session (just before surgery) we remeasured the major diameter using the same pachymeter and compared it to the tattooed initial margins. The clinical response to chemotherapy was evaluated according to RECIST criteria, adopted since 2002 for assessing chemotherapeutic response to solid tumor treatment. Individuals showing at least 30% tumor reduction are deemed responders and those showing less than 30% tumor reduction are considered to be non-responders (Therasse et al., 2000) .
Chemotherapy treatment consisted of three neoadjuvant administrations at 21-day intervals, following a 5-fluorouracil, epirubicin and cyclophosphamide scheme (FEC therapy).
Multiplex polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism
The genotypes of the GSTT1 and GSTM1 genes were determined by co-amplification using multiplex PCR, with the β-globin gene as an internal control, as described by Wilson et al. (2000) . The primers used were 5'-CTT CCT TAC TGG TCC TCA CAT CTC -3' (sense) and 5'-TCA CCG GAT CAT GGC CAG CA -3' (anti-sense) for the GSTT1 gene, resulting in a 480-bp fragment; 5'-GAA CTC CCT GAA AAG CTA AAG C -3' (sense) and 5'-CTT GGG CTC AAA TAT ACG GTG G -3' (anti-sense) for the GSTM1 gene, resulting in a 215-bp fragment, and 5'-GAA GAG CCA AGG ACA GGT AC -3' (sense) and 5'-CAA CTT CAT CCA CGT TCA CC -3' (antisense) for the β-globin gene, resulting in a 268-bp fragment. The GSTT1"null" and GSTM1"null" variant forms were defined by the absence of the 480-and 215-bp fragments, respectively. GSTP1 gene-related products were obtained by PCR-restriction fragment length polymorphism, with 5'-ACC CCA GGG CTC TAT GGG AA -3' (sense) and 5'-TGA GGG CAC AAG AAG CCC CT -3' (anti-sense) primer, which generates a 176-bp product. The amplified product was then submitted to digestion with the Alw26I enzyme (New England Biolabs, Ipswich, MA, USA), yielding 91-and 86-bp fragments for the GSTP1105Val homozygous genotypes, 176-, 91-and 86-bp fragments for the GSTP1Ile105Val heterozygous genotypes, and a 176-bp fragment for the wild-type GSTP1105Ile (Wilson et al., 2000) .
Statistical analysis
The first part of the analysis consisted in comparing clinical response with any isolated gene (wild-type and polymorphic) and all possible combinations of genes in pairs (wild-type and/ or polymorphic). The hypothesis test was used, where the null hypothesis was when there is no association between clinical response (RECIST) and the isolated or combined gene, i.e., these variables are independent. Cramer correlations and a non-parametric test of the chi-square test were used for categorical variables. The maximum value of this test is 1 and the minimum is 0. When the variables are independent, the value approaches 0. The data were input to the Statistical Program for the Social Sciences (SPSS, version 13.0, SPSS Inc., Chicago, IL, USA).
In the second part of the analysis, the test of equal proportions was used to analyze the variable clinical response (RECIST) between all possible combinations of genes in pairs (wild-type and/or polymorphic). We used the Microsoft Excel ® software. P < 0.05 was considered to be statistically significant for both tests.
RESULTS
Among the 40 patients studied, 24 (60%) were considered to be responders and 16 (40%) nonresponders according to RECIST criteria. Twenty-two patients (55%) showed the GSTT1 genotype, 18 (45%) the GSTT1"null" genotype; 26 (65%) the GSTM1 genotype, 14 (35%) the GSTM1"null" genotype, 18 (45%) the GSTP1 genotype, and 22 (55%) the GSTP1Ile105Val genotype.
Comparison of RECIST data for the genotype (individual genes) revealed no statistically significant difference in response between patients harboring either the polymorphic or the wild-type genotype (Table 2) . Table 2 . Frequencies of the wild-type and polymorphic-type GSTT1, GSTM1, and GSTP1 genes according to the RECIST classification. Comparison of data on the wild-type combinations against the respective polymorphictype combinations showed that eight patients (100%) with the GSTT1/GSTP1105Ile combination responded to treatment as did four patients (50%) with the GSTT1/GSTP1105Ile"null" combination, according to RECIST criteria (P = 0.0209) (Table 3) . When wild-type geno-type combinations were compared with each other, and polymorphic genotype combinations were also compared with each other, according to the "responder" RECIST variable, nine patients (60%) who had the GSTT1/GSTM1 combination and eight patients (100%) who had the GSTT1/GSTP1105Ile combination were found to be responders (P = 0.0376) (Table 4) . Finally, two-by-two analysis of all possible combinations of genes according to the number of responders, showed the polymorphic-type GSTM1"null" to be present in four (66.6%), and the wild-type GSTP1105Ile in three (50%) of the six combinations associated with the largest number of responders. In addition, the polymorphic-type GSTM1"null" was not present in any of the six combinations in patients with poor response to chemotherapy, while the wild-type GSTP1105Ile was only present in one of these six combinations (17%) ( Table 5) . Table 3 . Correlations between the numbers of responding patients according to the RECIST classification as to polymorphic-and their respective wild-type combinations of the GSTT1, GSTM1, and GSTP1 genes when combined in pairs. AN = absolute number of cases; R = number of responders. Table 4 . Correlations between all possible polymorphic type combinations and between all possible wild-type combinations according to the number of responding patients based on the RECIST classification. N = number of cases; R = number of responders.
Gene combination N R % of responders GSTT1/GSTP1Ile105Ile 8 8 100 GSTM1"null"/GSTP1Ile105Val 8 7 87.5 GSTT1/GSTM1"null" 7 6 85.7 GSTM1/GSTP1Ile105Ile 12 9 75 GSTT1"null"/GSTM1"null" 7 5 71.4 GSTM1"null"/GSTP1Ile105Ile 6 4 66.7 GSTT1/GSTM1 15 9 60 GSTT1/GSTP1Ile105Val 14 7 50 GSTT1"null"/GSTP1Ile105Val 8 4 50 GSTT1"null"/GSTP1Ile105ILe 10 5 50 GSTM1/GSTT1"null" 11 4 36.4 GSTM1/GSTP1Ile105Val 14 4 28.6 Table 5 . Percentages of responders according to combinations of genes in pairs in decreasing order of frequency. N = absolute number of patients observed for that combination; R = number of responders for that combination.
DISCUSSION
Since the first evidence that glutathione S-transferases are involved in response to chemotherapy (Schisselbauer et al., 1990; Tew, 1994; Hayes and Pulford, 1995) , the results of various subsequent studies have shown the inconsistent nature of this relationship (Riddick et al., 2005) . In the present study, we investigated the possible association between polymorphisms in the GSTT1, GSTM1 and GSTP1 genes and response to chemotherapy in Brazilian women with stage II and III breast cancer submitted to neoadjuvant FEC therapy. When analyzed individually, none of the genes showed a statistically significant relationship with response to chemotherapy according to the Cramer test. Similar results were found by other authors (Moscow et al., 1989; Leyland-Jones et al., 1991; Alpert et al., 1997; Morrow et al., 1998; Allan et al., 2001; Yang et al., 2005) . Lizard-Nacol et al., in 1999, studied 92 patients with breast cancer treated with neoadjuvant chemotherapy and did not find any association of clinical reduction of tumor size among patients with the wild-type or polymorphic form of GSTM1 genes. Yang et al., in 2005 , studied 1602 women with breast cancer submitted to adjuvant chemotherapy and also did not observe a statistical difference in response between wild-type and polymorphic forms of the GSTM1 and GSTT1 genes. Allan et al., in 2001 , studied the presence of acute myeloid leukemia in patients submitted to chemotherapy and did not observe a greater incidence of that disease when compared to patients with wild-type or polymorphic forms of the GSTT1 and GSTM1 genes.
However, when we combined the genes in pairs, the variant-type GSTM1"null" was present in four and the wild-type GSTP1105Ile in six of the combinations with the largest percentage of responders. Furthermore, in the six combinations with the lowest percentage of responders, the polymorphic-type GSTM1"null" was not present, while the wild-type GSTP1105Ile was present in only one combination. These results were also found by other authors when the GSTM1 gene was analyzed individually (Hamada et al., 1994; Morrow et al., 1998; O'Brien et al., 2000; Allan et al., 2001; Naoe et al., 2002; Huang et al., 2003; Yang et al., 2005) , but were not replicated in the case of the GSTP1 gene. When the "responder" variable in the RECIST classification was used in comparing wild-type combinations with their respective variant polymorphic combinations, eight patients (100%) with the GSTT1/GSTP1105Ile combination and four patients (50%) with the GSTT1"null"/GSTP1105Val combination proved to be responders according to an analysis based on the test of equal proportions (P = 0.0209). When the wild-type combinations were compared with each other, and the variant-type combinations were also compared with each other, nine patients (60%) with the GSTT1/GSTM1 combination and eight patients (100%) with the GSTT1/GSTP1105Ile combination proved to be responders based on the test of equal proportions (P = 0.0376). These results suggest that the wild-type combination GSTT1/GSTP1105Ile was more sensitive to the chemotherapy used in this study. Our results are thus in contrast with those of other authors (Dirven, 1994; Tew, 1994; Howells et al., 2001; Paumi et al., 2001; Naoe et al., 2002; Khedhaier et al., 2003; Townsend and Tew, 2003a,b) who either found that the wild-types were more resistant than polymorphic forms or found no significant differences. Ambrosone et al., in 2001 , conducted a retrospective study of breast cancer patients submitted to chemotherapy and noted greater recurrence-free survival among women who showed the polymorphic form of the GSTT1 and GSTM1 genes when compared to that with wild-type forms, thus in contrast with findings of other authors. Allan et al., in 2001 , noted that acute myeloid leukemia was significantly more severe among patients who had the polymorphic form of the GSTP1 gene than patients with the wild-type form of the gene. Khedhaier et al., in 2003 , studied 309 breast cancer patients submitted to neoadjuvant chemotherapy and noted greater recurrence-free survival among patients who had the polymorphic form of the GSTT1 and GSTM1 genes, than patients with the wild form of genes. Yang et al., in 2005 Yang et al., in , studied 1602 breast cancer patients submitted to adjuvant chemotherapy and also noted greater recurrencefree survival among women with the polymorphic form of the GSTP1 gene.
As the wild-type genes are able to produce detoxifying enzymes that act in the metabolism of chemotherapeutic drugs and do take part in the inhibition of the JNK1 apoptosis pathway (Adler et al., 1999; Dang et al., 2005; McIlwain et al., 2006) , our results were unexpected. Maybe a highly mixed racial origin represents a unique response to chemotherapy by Brazilian women, or other genetic factors related or not to the metabolism of drugs are involved. When interpreting these results, it should be borne in mind that this was a prospective study, and a larger sample is needed to guarantee statistical validity. Our results are drawn from an initial study, and further studies are warranted for confirmation.
